4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
NextCure, Inc. (NXTC) operates in the Biotechnology industry and is headquartered in Beltsville, United States with about 40 employees. Its market capitalization is roughly $7 million. In the fiscal year ended 2025-12-31, NXTC reported $0M in revenue and ($56M) in net income.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($58M) | ($57M) | ($68M) | ($76M) |
| Net Income | ($56M) | ($56M) | ($63M) | ($75M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($10M) | ($10M) | ($9M) | ($27M) | ($12M) | — |
| Net Income | ($10M) | ($9M) | ($9M) | ($27M) | ($11M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $50M | $81M | $128M | $184M | — |
| Total Liabilities | $15M | $15M | $14M | $17M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NXTC viewer.
About TickerBase · Data methodology & sources